Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Can Wegovy cause gallbladder problems?

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Yes — gallbladder problems (gallstones, cholecystitis) are a known risk on GLP-1 medications, including Wegovy. The mechanism: rapid weight loss alters bile composition, increasing cholesterol saturation and gallstone formation. Risk is higher in patients losing weight quickly, those with prior gallbladder symptoms, those with high BMI before treatment, and women. Symptoms include right-upper-quadrant abdominal pain (especially after fatty meals), nausea, vomiting, fever, and yellowing of skin or eyes. Severe acute pain can indicate cholecystitis (gallbladder inflammation), which is an emergency. Strategies that reduce risk: slow weight-loss pace, maintain adequate fat intake (very low-fat diets paradoxically increase gallstone risk), and stay hydrated. If you develop symptoms, contact your prescriber promptly; ultrasound imaging confirms diagnosis. Gallbladder removal may be necessary for symptomatic stones; this typically does not require stopping Wegovy long-term.

Where to start

Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.

  • Ro logo

    Ro

    from $145/mo
    • Best for insured patients
    • Best for clinical oversight

    Ro Body — branded GLP-1 weight care program

  • Hims logo

    Hims

    from $199/mo
    • Best for cash-pay
    • Best for speed

    Hims Weight Loss — compounded GLP-1 from $199/mo

  • Noom Med logo

    Noom Med

    from $179/mo
    • Best for coaching
    • Best for maintenance

    Noom Med — GLP-1 + behavioral psychology coaching

Drugs referenced

Related questions

  • What are the most common Wegovy side effects?

    The most common Wegovy side effects are gastrointestinal: nausea (40-44% of trial patients), diarrhea (30%), vomiting (24%), and constipation (24%). These typically peak during dose escalation in the first 4-8 weeks and improve as the body adapts. Less common but serious risks include gallbladder problems, pancreatitis, kidney strain (especially if dehydrate

We may earn a commission when you click links to partners. Affiliate disclosure.